Join to invest

Already registered? Log in

732%

Intellin® is an intelligent remote management diabetes platform, with over 140,000 downloads so far this year. Having established themselves as an approved vendor with Big Pharma, they're now poised to scale the business globally and drive commercialisation.

  • Over 140,000 downloads in 170 countries
  • Designed for remote monitoring – healthcare team to patient – critical post COVID19
  • A novel platform that uses clinical history to predict risk
  • Gendius is an approved vendor for AstraZeneca Saudi Arabia

Idea

What is Intellin?

Since our last successful appearance on Crowdcube last year, intellin® has established itself as a growing presence in diabetes management. In the last three months, intellin® has been downloaded over 140,000 times by those seeking better management of diabetes.

The COVID-19 crisis has highlighted the need for remote home monitoring of patients. Dr Martin Marshall, (Chair, RCGP) said that ‘Having the technological capability to offer remote consultations, where appropriate, will be beneficial for general practice, the wider NHS and most importantly our patients, long after this pandemic has ended’. Intellin® has connection to over 150 medical devices and apps, and two-way communication with the Healthcare Professional via a secure dashboard leaves intellin® with the potential to play an important role going forward. We are part-way through a trial in a GP practice and are now ready to discuss our offering with the wider NHS. We are registered as an approved vendor with AstraZeneca in Saudi Arabia and aim to use this as a springboard to other opportunities.

We are now planning a £5m investment round to scale the business globally and drive commercialisation. We are keen to offer this opportunity to the Crowd who have already supported the business before we then target Venture Capital for the remaining funding.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Gendius pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

Risk warning

Investing in start-ups and early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Crowdcube is targeted exclusively at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. You will only be able to invest via Crowdcube once you are registered as sufficiently sophisticated. Please click here to read the full Risk Warning.

Crowdcube is authorised and regulated by the Financial Conduct Authority (FCA) and the Comisión Nacional del Mercado de Valores (CNMV). This page has been approved by Crowdcube. Pitches for investment are not offers to the public and investments can only be made by members of crowdcube.com on the basis of information provided in the pitches by the companies concerned. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Gendius has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.